Technical Analysis for BJDX - Bluejay Diagnostics, Inc.

Grade Last Price % Change Price Change
C 3.52 0.57% 0.02
BJDX closed up 0.57 percent on Friday, November 22, 2024, on 1 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Gapped Down Weakness 0.00%
Upper Bollinger Band Walk Strength 0.57%
Wide Bands Range Expansion 0.57%
Above Upper BB Strength 0.57%
Overbought Stochastic Strength 0.57%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High 1 day ago
Up 10% 1 day ago
Up 1 ATR 1 day ago
Possible Inside Day 1 day ago
Up 5% 1 day ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Bluejay Diagnostics, Inc. Description

Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.


Classification

Sector: Healthcare
Industry: Medical Devices
Keywords: Medicine Biotechnology Cancer Clinical Medicine Infectious Diseases Inflammation Allergy Biomarkers Allergic Conjunctivitis Chemical Pathology Congestive Heart Failure Sepsis Conjunctivitis Lyme Disease Tick Borne Diseases

Is BJDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 31.28
52 Week Low 0.0652
Average Volume 20,348,042
200-Day Moving Average 2.64
50-Day Moving Average 0.45
20-Day Moving Average 0.94
10-Day Moving Average 1.79
Average True Range 0.39
RSI (14) 86.67
ADX 51.99
+DI 63.87
-DI 2.39
Chandelier Exit (Long, 3 ATRs) 2.90
Chandelier Exit (Short, 3 ATRs) 1.23
Upper Bollinger Bands 3.88
Lower Bollinger Band -2.00
Percent B (%b) 0.94
BandWidth 625.07
MACD Line 0.83
MACD Signal Line 0.43
MACD Histogram 0.3988
Fundamentals Value
Market Cap 6.25 Million
Num Shares 1.78 Million
EPS -9.64
Price-to-Earnings (P/E) Ratio -0.37
Price-to-Sales 34.80
Price-to-Book 0.26
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.50
Resistance 3 (R3) 4.55 4.27 4.34
Resistance 2 (R2) 4.27 4.02 4.25 4.28
Resistance 1 (R1) 3.90 3.87 4.08 3.85 4.23
Pivot Point 3.62 3.62 3.71 3.59 3.62
Support 1 (S1) 3.24 3.37 3.43 3.19 2.81
Support 2 (S2) 2.96 3.21 2.94 2.76
Support 3 (S3) 2.59 2.96 2.70
Support 4 (S4) 2.54